Cervical Cancer: From Molecular and Cellular Mechanisms to Therapeutic Opportunities
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Reproductive Cells and Development".
Deadline for manuscript submissions: closed (1 April 2022) | Viewed by 7197
Special Issue Editors
Interests: ovarian cancer; cervical cancer; endometrial cancer; vulvar cancer; vagina cancer; gestational trophoblastic disease
Interests: ovarian cancer; target therapies; chemotherapy; homologous recombination; BRCA; platinum resistance; PARP inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cervical cancer is a malignant tumor and is the fourth most common cancer among women worldwide. Since the introduction of angiogenesis inhibitors, treatment for recurrent and advanced cervical cancers has improved in the past five years, but overall survival is still poor.
Therefore, several areas of cervical cancer research continue to address the challenges of identifying appropriate therapeutic alternatives. With this regard, exploration of pathogenesis and molecular mechanism of cervical cancer is pivotal; moreover, also the knowledge of immune system adaption in affected patients is essential, as the local immune response is considered a key determinant in cervical carcinogenesis after persistent infection with oncogenic, high-risk human papillomavirus (HPV) infections. Multifactorial etiology of cervical cancer requires a combined approach, involving many disciplines, from molecular genetics, to immunotherapy and beyond…
For this Special Issue, we welcome basic translational, professional opinions, and reviews in the broad field of cervical cancer. Our goal is to use this information collected to improve cervical cancer management in the future but also to help researchers in designing new trials with personalized therapeutic strategies for patients affected by cervical cancer.
Dr. Domenica Lorusso
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cervical cancer
- carcinogenesis
- genetic
- vaccination
- immunecheckpoint inhibitor
- molecular mechanism
- molecular biomarkers
